Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid [Seeking Alpha]
Omeros Corporation (OMER)
Last omeros corporation earnings: 3/2 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.omeros.com
Company Research
Source: Seeking Alpha
The deal extends OMER's cash runway through 2027, allowing focus on narsoplimab, which awaits a key FDA decision for HSCT-TMA in December 2025. Zaltenibart's out-license validates OMER's approach, but future prospects hinge on narsoplimab approval; the stock now has a more favorable risk-reward profile for a covered call trade. While not for risk-averse investors, OMER is attractive for small, covered call trades, with options liquidity and potential upside on regulatory success. MadamLead/iStock via Getty Images Shares of biotech concern Omeros Corporation ( OMER ) moved up sharply on Oct. 15, 2025, after announcing a significant out-licensing deal with Novo Nordisk ( NVO ) for its MASP-3 inhibitor. The exclusive rights to More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free t
Show less
Read more
Impact Snapshot
Event Time:
OMER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OMER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OMER alerts
High impacting Omeros Corporation news events
Weekly update
A roundup of the hottest topics
OMER
News
- Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.MarketBeat
- Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) [Yahoo! Finance]Yahoo! Finance
- Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)Business Wire
- Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.MarketBeat
OMER
Earnings
- 11/13/25 - Beat
OMER
Sec Filings
- 12/1/25 - Form 8-K
- 11/14/25 - Form 424B5
- 11/14/25 - Form S-3ASR
- OMER's page on the SEC website